AnaptysBio, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- AnaptysBio, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on developing innovative therapeutic antibody candidates for a variety of autoimmune and inflammatory conditions. The company's internal pipeline encompasses several key assets designed to modulate immune system pathways. Rosnilimab, an IgG1 antibody aimed at depleting pathogenic T cells, has delivered positive Phase 2b data in rheumatoid arthritis, though its Phase 2 study for ulcerative colitis did not meet efficacy endpoints and will be discontinued. Another asset, ANB033, a CD122 antagonist antibody, is progressing through a Phase 1b trial for celiac disease, with expansion into additional indications being explored. Furthermore, ANB101, a BDCA2 modulator antibody, is in Phase 1 clinical assessment, focusing on inflammatory disorders involving plasmacytoid dendritic cells. In addition to its proprietary programs, AnaptysBio has formed significant collaborations for out-licensed antibodies. Imsidolimab, an IL-36 receptor antagonist, is currently undergoing Phase 3 development for generalized pustular psoriasis through a partnership with Vanda Pharmaceuticals. The company also benefits from royalties and potential milestone payments from GSK related to Jemperli (dostarlimab-gxly), a PD-1 antagonist originally discovered by AnaptysBio and now approved for certain oncology indications. Recently, AnaptysBio announced plans to strategically separate its biopharma operations from its substantial royalty assets by the end of 2026, aiming to establish two distinct publicly traded companies. The company has also filed a lawsuit against Tesaro, a GSK subsidiary, asserting breaches of their collaboration agreement pertaining to Jemperli. Originally established in 2005, AnaptysBio, Inc. maintains its operational base in San Diego, California.
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
AnaptysBio (NASDAQ:ANAB) Director John Schmid Sells 20,645 Shares of Stock
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement